Cargando…
Therapeutic Interaction of Apatinib and Chidamide in T-cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis
T-cell acute lymphoblastic leukemia (T-ALL) shows poor clinical outcome and has limited therapeutic options, indicating that new treatment approaches for this disease are urgently required. Our previous study demonstrated that apatinib, an orally selective VEGFR-2 antagonist, is highly effective in...
Autores principales: | Zhong, Mengya, Lin, Fusheng, Jiang, Yuelong, Pan, Guangchao, Tan, Jinshui, Zhou, Hui, Lai, Qian, Chen, Qinwei, Deng, Manman, Zha, Jie, Xu, Bing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540063/ https://www.ncbi.nlm.nih.gov/pubmed/34683119 http://dx.doi.org/10.3390/jpm11100977 |
Ejemplares similares
-
Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells
por: Zhao, Haijun, et al.
Publicado: (2022) -
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021) -
Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia
por: Deng, Manman, et al.
Publicado: (2018) -
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
por: Chen, Kai, et al.
Publicado: (2020) -
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways
por: Chen, Qinwei, et al.
Publicado: (2022)